Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
34.41B
Market cap34.41B
Price-Earnings ratio
-25.02
Price-Earnings ratio-25.02
Dividend yield
Dividend yield
Average volume
2.78M
Average volume2.78M
High today
$160.49
High today$160.49
Low today
$157.75
Low today$157.75
Open price
$159.10
Open price$159.10
Volume
1.56M
Volume1.56M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $159.59. The company's market cap stands at 34.41B, with a P/E ratio of -25.02.

On 2026-04-09, Insmed Incorporated(INSM) stock moved within a range of $157.75 to $160.49. With shares now at $159.59, the stock is trading +1.2% above its intraday low and -0.6% below the session's peak.

Trading volume for Insmed Incorporated(INSM) stock has reached 1.56M, versus its average volume of 2.78M.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

INSM News

Simply Wall St 17h
Should Insmed’s Brensocatib Setback in Hidradenitis Suppurativa Require Action From Investors?

Insmed announced that its Phase 2b CEDAR study of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary or secondary eff...

Should Insmed’s Brensocatib Setback in Hidradenitis Suppurativa Require Action From Investors?
TipRanks 1d
Insmed price target lowered to $202 from $206 at Mizuho

Mizuho lowered the firm’s price target on Insmed (INSM) to $202 from $206 and keeps an Outperform rating on the shares. The company announced negative Phase 2b...

Benzinga 1d
Insmed Drug Misses Primary Goal, Program Axed

Insmed Incorporated (NASDAQ:INSM) on Tuesday shared the Phase 2b CEDAR study results for brensocatib. The study did not meet its primary or secondary efficacy...

Insmed Drug Misses Primary Goal, Program Axed

Analyst ratings

100%

of 21 ratings
Buy
100%
Hold
0%
Sell
0%

More INSM News

Seeking Alpha 1d
Insmed drops skin disorder candidate after mid-stage trial setback

Insmed Incorporated (INSM) has decided to halt an R&D program for its lung disorder therapy, brensocatib, following a mid-stage trial failure for the candidate...

Insmed drops skin disorder candidate after mid-stage trial setback
TipRanks 2d
Insmed price target raised to $212 from $203 at RBC Capital

RBC Capital raised the firm’s price target on Insmed (INSM) to $212 from $203 and keeps an Outperform rating on the shares as part of the firm’s broader researc...

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.